[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352394-105":59,"doc-detail-352394-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","article-identification-and-experimental-validation-of-triosephosphate-isomerase-1-as-a-functional-biomarker-of-sheta2-sensitivity-in-ovarian-cancer","Article - Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer","","Background: The study aims to identify and validate proteins predicting response of ovarian cancer to SHetA2, an investigational phase 1 drug. Methods: Ascites-derived cultures from nine consented patients and ovarian cancer cell lines were tested for SHetA2 or olaparib sensitivity using metabolic viability assays. Four SHetA2 target proteins plus sixteen ovarian mouse model proteins were quantified, with TPI1 modulated by siRNA or lentiviral overexpression; metabolites were profiled by mass spectrometry. Results: TPI1 elevation correlated with SHetA2 sensitivity and altered drug potency; downstream glycolysis, TCA, and oxidative PPP metabolites decreased with SHetA2. Conclusions: TPI1 is a candidate functional biomarker of SHetA2 sensitivity in ovarian cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/article-identification-and-experimental-validation-of-triosephosphate-isomerase-1-as-a-functional-biomarker-of-sheta2-sensitivity-in-ovarian-cancer/352394/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/article-identification-and-experimental-validation-of-triosephosphate-isomerase-1-as-a-functional-biomarker-of-sheta2-sensitivity-in-ovarian-cancer/352394.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s primary objective regarding SHetA2 in ovarian cancer?","Question",{"text":112,"@type":113},"To identify and validate proteins that predict which ovarian cancer patients will respond to SHetA2.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were SHetA2 or olaparib sensitivities determined in the study?",{"text":117,"@type":113},"Through metabolic viability assays using ascites-derived cultures and ovarian cancer cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What role did TPI1 play in relation to SHetA2 sensitivity?",{"text":121,"@type":113},"TPI1 was higher in SHetA2-sensitive ascites-derived cultures, and altering TPI1 levels reduced or increased SHetA2 potency in ovarian cancer cell lines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352394,1790512271,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nIdentification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer  \nLaura F. Mortan 1,2, Zitha Redempta Isingizwe 1,3 and Doris Mangiaracina Benbrook 1,2,3, *  \nAcademic Editors: Concettina La Motta, Yuhao Xie and Rakesh Kumar Srivastava  \nReceived: 13 December 2025  \nRevised: 24 January 2026  \nAccepted: 29 January 2026  \nPublished: 30 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA; [laura-mortan@ou.edu](laura-mortan@ou.edu) (L.F.M.); [zitha-isingizwe@ou.edu](zitha-isingizwe@ou.edu) (Z.R.I.)  \n2 Pathology Department, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA  \n3 Obstetrics and Gynecology Department, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA  \n* Correspondence: [doris-benbrook@ou.edu](doris-benbrook@ou.edu); Tel.: +1-405-271-5523  \nAbstract  \nBackground: Our objective was to identify and validate proteins that predict which patients with ovarian cancer will respond to SHetA2, an investigational drug in a phase 1 trial for patients with advanced or recurrent solid tumors ([clinicaltrials.gov: NCT04928508](clinicaltrials.gov: NCT04928508)). Methods: Cells were cultured from ascites from nine consented patients under an institutional review board-approved protocol. SHetA2 or olaparib sensitivities were determined using metabolic viability assays in ascites-derived cultures or ovarian cancer cell lines. Expression of four SHetA2 target proteins and sixteen proteins previously identified in an ovarian cancer mouse model were measured using microcapillary electrophoresis. Triosephosphate isomerase 1 (TPI1) was modulated by siRNA or lentivirus vector-mediated overexpression. Metabolites were measured using mass spectrometry. Results: TPI1 was elevated in SHetA2-sensitive compared to SHetA2-resistant ascites-derived cultures (two-way ANOVA q-value = 0.0003) . The majority of (5/9) cultures were olaparib-resistant and SHetA2-sensitive. TPI1 was higher in olaparib-resistant cultures (two-way ANOVA q-value = 0.0003) . Reduction in or overexpression of TPI1 reduced or increased SHetA2 potency, respectively, in two ovarian cancer cell lines (t-tests; p \u003C 0.05) . SHetA2 reduced the metabolites in glycolysis downstream of TPI1, the tricarboxylic acid cycle and oxidative pentose phosphate pathway. Conclusions: TPI1 is a candidate functional biomarker of SHetA2 sensitivity in ovarian cancer.  \nKeywords: high grade serous ovarian carcinoma; ascites; SHetA2; olaparib; triosephosphate isomerase 1; biomarker; glycolysis; pentose phosphate pathway; TCA cycle; spheroids  \n1. Introduction  \nOvarian cancer is one of the leading causes of cancer deaths among women [1,2] . Owing to the lack of specific symptoms and early detection strategies, more than half of the estimated 20,000 patients with ovarian cancer are diagnosed at an advanced stage. Current standard of care for advanced ovarian cancer involves surgical debulking followed by six cycles of platinum-based doublet chemotherapy, with the potential to include targeted therapy [3,4] . Targeted therapies consist of antiangiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors, olaparib, rucaparib, and niraparib [5] . Most patients with stage III or IV ovarian cancer will undergo a period of remission before having a recurrence  \nof their cancer, resulting in a five-year survival rate of only 25%[1,5,6] . Research into the biology of ovarian cancer provides insight into the mechanisms of this high rate of recurrence.  \nOvarian cancer is a heterogenous disease consisting of multiple histologies arising from different organ sites [7,8] . High-grad","cbCaiuCQFUgCQT6f","https://ap.wps.com/l/cbCaiuCQFUgCQT6f","pdf",5338272,23,"English","# Abstract\n# 1. Introduction","[{\"question\":\"What was the study’s primary objective regarding SHetA2 in ovarian cancer?\",\"answer\":\"To identify and validate proteins that predict which ovarian cancer patients will respond to SHetA2.\"},{\"question\":\"How were SHetA2 or olaparib sensitivities determined in the study?\",\"answer\":\"Through metabolic viability assays using ascites-derived cultures and ovarian cancer cell lines.\"},{\"question\":\"What role did TPI1 play in relation to SHetA2 sensitivity?\",\"answer\":\"TPI1 was higher in SHetA2-sensitive ascites-derived cultures, and altering TPI1 levels reduced or increased SHetA2 potency in ovarian cancer cell lines.\"}]","Article - Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer | PDF",1790099344,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5fb179fa5b90c15ce816a2a75c3e5f2.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fbf11baa0c2e23e21513b9624dcc783.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64bf295434ef120c222002d6666f4071.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6eeaba7ff8d063e233c3587246af781.webp",980,1385]